Thomas Jefferson University

Sucha Asbell

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address833 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mahadevan A, Emami B, Grimm J, Kleinberg LR, Redmond KJ, Welsh JS, Rostock R, Kemmerer E, Forster KM, Stanford J, Shah S, Asbell SO, LaCouture TA, Scofield C, Butterwick I, Xue J, Muacevic A, Adler JR. Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models. Front Oncol. 2020; 10:591430. PMID: 33634020.
      Citations:    
    2. Xu Q, Fan J, Grimm J, LaCouture T, Asbell S, Park JH, Kubicek G. The dosimetric impact of the prescription isodose line (IDL) on the quality of robotic stereotactic radiosurgery (SRS) plans. Med Phys. 2017 Dec; 44(12):6159-6165. PMID: 29064585.
      Citations:    
    3. Peterson J, Niles C, Patel A, Boujaoude Z, Abouzgheib W, Goldsmith B, Asbell S, Xu Q, Khrizman P, Kubicek GJ. Stereotactic Body Radiotherapy for Large (> 5 cm) Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 07; 18(4):396-400. PMID: 28040379.
      Citations:    
    4. Xue J, Kubicek G, Patel A, Goldsmith B, Asbell SO, LaCouture TA. Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels. Semin Radiat Oncol. 2016 Apr; 26(2):135-9. PMID: 27000510.
      Citations:    
    5. LaCouture TA, Xue J, Subedi G, Xu Q, Lee JT, Kubicek G, Asbell SO. Small Bowel Dose Tolerance for Stereotactic Body Radiation Therapy. Semin Radiat Oncol. 2016 Apr; 26(2):157-64. PMID: 27000513.
      Citations:    
    6. Asbell SO, Grimm J, Xue J, Chew MS, LaCouture TA. Introduction and Clinical Overview of the DVH Risk Map. Semin Radiat Oncol. 2016 Apr; 26(2):89-96. PMID: 27000504.
      Citations:    
    7. Subedi G, Karasick T, Grimm J, Jain S, Xue J, Xu Q, Chen Y, Asbell S, Pahlajani N, LaCouture T. Factors that may determine the targeting accuracy of image-guided radiosurgery. Med Phys. 2015 Oct; 42(10):6004-10. PMID: 26429275.
      Citations:    
    8. Xu Q, Hanna G, Grimm J, Kubicek G, Pahlajani N, Asbell S, Fan J, Chen Y, LaCouture T. Quantifying rigid and nonrigid motion of liver tumors during stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Sep 01; 90(1):94-101. PMID: 25195990.
      Citations:    
    9. Kubicek GJ, Xue J, Xu Q, Asbell SO, Hughes L, Kramer N, Youssef A, Chen Y, Aikens J, Saul H, Pahlajani N, LaCouture T. Stereotactic body radiotherapy as an alternative to brachytherapy in gynecologic cancer. Biomed Res Int. 2013; 2013:898953. PMID: 24000329.
      Citations:    
    10. Srivastava R, Asbell SO, Lacouture T, Kramer N, Pahlajani N, Xue J, Ahmad N, Chen Y, Croce R, Grimm J. Low toxicity for lung tumors near the mediastinum treated with stereotactic body radiation therapy. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):130-7. PMID: 24674316.
      Citations:    
    11. Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM. The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02. Clin Cancer Res. 2009 Sep 01; 15(17):5478-84. PMID: 19706804.
      Citations:    
    12. Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):672-8. PMID: 18990504.
      Citations:    
    13. Chakravarti A, DeSilvio M, Zhang M, Grignon D, Rosenthal S, Asbell SO, Hanks G, Sandler HM, Khor LY, Pollack A, Shipley W. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol. 2007 Jul 20; 25(21):3082-9. PMID: 17634487.
      Citations:    
    14. Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):646-55. PMID: 17531401.
      Citations:    
    15. Small W, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, Erickson B, Jhingran A, Greven K. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1081-7. PMID: 17398031.
      Citations:    
    16. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR, Shipley WU. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):647-53. PMID: 17011443.
      Citations:    
    17. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005 Apr 01; 61(5):1285-90. PMID: 15817329.
      Citations:    
    18. Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, John M, Herskovic A, Urtasun R, Asbell SO, Perez CA, Cox J. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer. 2003 Aug; 41(2):207-14. PMID: 12871784.
      Citations:    
    19. Roach M, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR, Shipley WS. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003 May 15; 21(10):1904-11. PMID: 12743142.
      Citations:    
    20. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003 Jan; 169(1):245-50. PMID: 12478146.
      Citations:    
    21. Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96(6):363-71. PMID: 11745507.
      Citations:    
    22. Werner-Wasik M, Scott C, Cox JD, Sause WT, Byhardt RW, Asbell S, Russell A, Komaki R, Lee JS. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000 Dec 01; 48(5):1475-82. PMID: 11121651.
      Citations:    
    23. Asbell SO, Raimane KC, Montesano AT, Zeitzer KL, Asbell MD, Vijayakumar S. Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients. J Natl Med Assoc. 2000 Sep; 92(9):445-9. PMID: 11052458.
      Citations:    
    24. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000 Jul; 18(14):2740-6. PMID: 10894874.
      Citations:    
    25. Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W, Cox J, Mohuidden M. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000 Jun 01; 47(3):617-27. PMID: 10837944.
      Citations:    
    26. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Mohuidden M. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000 Jun 01; 47(3):609-15. PMID: 10837943.
      Citations:    
    27. Kalapurakal JA, Jacob AN, Kim PY, Najjar DD, Hsieh YC, Ginsberg P, Daskal I, Asbell SO, Kandpal RP. Racial differences in prostate cancer related to loss of heterozygosity on chromosome 8p12-23. Int J Radiat Oncol Biol Phys. 1999 Nov 01; 45(4):835-40. PMID: 10571186.
      Citations:    
    28. Streeter OE, Martz KL, Gaspar LE, Delrowe JD, Asbell SO, Salter MM, Roach M. Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01? Int J Radiat Oncol Biol Phys. 1999 Jul 15; 44(5):1047-52. PMID: 10421537.
      Citations:    
    29. Grigsby PW, Winter K, Wasserman TH, Marcial V, Rotman M, Cooper J, Keys H, Asbell SO, Phillips TL. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1999 Jun 01; 44(3):513-7. PMID: 10348279.
      Citations:    
    30. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999 May 05; 281(17):1623-7. PMID: 10235156.
      Citations:    
    31. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D. Long-term survival after radiotherapy alone: radiation therapy oncology group prostate cancer trials. J Urol. 1999 Mar; 161(3):864-8. PMID: 10022702.
      Citations:    
    32. Komaki R, Scott CB, Byhardt R, Emami B, Asbell SO, Russell AH, Roach M, Parliament MB, Gaspar LE. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1998 Sep 01; 42(2):263-7. PMID: 9788403.
      Citations:    
    33. Abrams RA, Pajak TF, Haulk TL, Flam M, Asbell SO. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am. 1998 May-Jun; 4(3):178-84. PMID: 9612600.
      Citations:    
    34. Asbell SO, Martz KL, Shin KH, Sause WT, Doggett RL, Perez CA, Pilepich MV. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998 Mar 01; 40(4):769-82. PMID: 9531360.
      Citations:    
    35. Prados MD, Scott CB, Rotman M, Rubin P, Murray K, Sause W, Asbell S, Comis R, Curran W, Nelson J, Davis RL, Levin VA, Lamborn K, Phillips TL. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1998 Feb 01; 40(3):653-9. PMID: 9486616.
      Citations:    
    36. Komaki R, Scott C, Lee JS, Urtasun RC, Byhardt RW, Emami B, Andras EJ, Asbell SO, Rotman M, Cox JD. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06. Am J Clin Oncol. 1997 Oct; 20(5):435-40. PMID: 9345325.
      Citations:    
    37. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF, Banker FL, Earle JD, Fischbach JA, Asbell SO, Gaspar LE, Markoe AM, Curran W. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys. 1997 Jul 15; 38(5):911-4. PMID: 9276354.
      Citations:    
    38. Asbell SO, Vijayakumar S. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Prostate. 1997 Apr 01; 31(1):42-6. PMID: 9108885.
      Citations:    
    39. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 Mar 01; 37(4):745-51. PMID: 9128946.
      Citations:    
    40. Jayaraman S, Asbell SO. Dose-volume histograms can be interpreted in different ways. Cancer Invest. 1997; 15(6):611-3. PMID: 9412668.
      Citations:    
    41. Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate. 1996 Oct; 29(4):243-8. PMID: 8876707.
      Citations:    
    42. Cooper JS, Farnan NC, Asbell SO, Rotman M, Marcial V, Fu KK, McKenna WG, Emami B. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer. 1996 May 01; 77(9):1905-11. PMID: 8646692.
      Citations:    
    43. Simpson JR, Scott CB, Rotman M, Curran WJ, Constine LS, Fischbach AJ, Asbell SO. Race and prognosis of brain tumor patients entering multicenter clinical trials. A report from the Radiation Therapy Oncology Group. Am J Clin Oncol. 1996 Apr; 19(2):114-20. PMID: 8610632.
      Citations:    
    44. Emami B, Scott C, Perez CA, Asbell S, Swift P, Grigsby P, Montesano A, Rubin P, Curran W, Delrowe J, Arastu H, Fu K, Moros E. Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors. A prospectively controlled randomized study by the Radiation Therapy Group. Int J Radiat Oncol Biol Phys. 1996 Mar 15; 34(5):1097-104. PMID: 8600093.
      Citations:    
    45. Fu KK, Pajak TF, Marcial VA, Ortiz HG, Rotman M, Asbell SO, Coia LR, Vora NL, Byhardt R, Rubin P, et al. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys. 1995 Jun 15; 32(3):577-88. PMID: 7790242.
      Citations:    
    46. Corn BW, Yousem DM, Scott CB, Rotman M, Asbell SO, Nelson DF, Martin L, Curran WJ. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). Cancer. 1994 Nov 15; 74(10):2828-35. PMID: 7954244.
      Citations:    
    47. Shipley WU, Zietman AL, Hanks GE, Coen JJ, Caplan RJ, Won M, Zagars GK, Asbell SO. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol. 1994 Nov; 152(5 Pt 2):1799-805. PMID: 7933239.
      Citations:    
    48. Hanks GE, Perez CA, Kozar M, Asbell SO, Pilepich MV, Pajak TF. PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):289-92. PMID: 7523341.
      Citations:    
    49. Hanks GE, Krall JM, Hanlon AL, Asbell SO, Pilepich MV, Owen JB. Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys. 1994 Jan 01; 28(1):39-45. PMID: 8270458.
      Citations:    
    50. Perez CA, Scott C, Emami B, Hornback NB, Sneed PK, Asbell SO, Janjan NA. Evaluation of 45 degrees C hyperthermia and irradiation. II. A phase I clinical trial in humans by the Radiation Therapy Oncology Group. Am J Clin Oncol. 1993 Dec; 16(6):477-81. PMID: 8256760.
      Citations:    
    51. Komaki R, Pajak TF, Byhardt RW, Emami B, Asbell SO, Roach M, Pedersen JE, Curran WJ, Lattin P, Russell AH, et al. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. Lung Cancer. 1993 Dec; 10(3-4):189-97. PMID: 8075966.
      Citations:    
    52. Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):493-8. PMID: 8226140.
      Citations:    
    53. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993 May 20; 26(2):239-44. PMID: 8387988.
      Citations:    
    54. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993 May 05; 85(9):704-10. PMID: 8478956.
      Citations:    
    55. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, Martz K, Venner P, Hammond E. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993 Apr 02; 25(5):783-90. PMID: 8478228.
      Citations:    
    56. Swift PS, Phillips T, Martz K, Wara W, Mohiuddin M, Chang CH, Asbell SO. CT characteristics of patients with brain metastases treated in RTOG study 79-16. Int J Radiat Oncol Biol Phys. 1993 Jan 15; 25(2):209-14. PMID: 8420868.
      Citations:    
    57. Graham MV, Geitz LM, Byhardt R, Asbell S, Roach M, Urtasun RC, Curran WJ, Lattin P, Russell AH, Cox JD. Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer. J Natl Cancer Inst. 1992 Nov 18; 84(22):1731-5. PMID: 1331484.
      Citations:    
    58. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Nelson DF, Fischbach AJ, Chang CH, Rotman M, Asbell SO, et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol. 1992 Mar; 12(3):219-27. PMID: 1583555.
      Citations:    
    59. Hanks GE, Krall JM, Pilepich MV, Asbell SO, Perez CA, Rubin P, Sause WT, Doggett RL. Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: implications of RTOG data for patient management and trial design and stratification. Int J Radiat Oncol Biol Phys. 1992; 23(2):293-8. PMID: 1587749.
      Citations:    
    60. Roach M, Krall J, Keller JW, Perez CA, Sause WT, Doggett RL, Rotman M, Russ H, Pilepich MV, Asbell SO, et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys. 1992; 24(3):441-9. PMID: 1399729.
      Citations:    
    61. Hanks GE, Asbell S, Krall JM, Perez CA, Doggett S, Rubin P, Sause W, Pilepich MV. Outcome for lymph node dissection negative T-1b, T-2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys. 1991 Sep; 21(4):1099-103. PMID: 1917610.
      Citations:    
    62. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SR, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991 Sep; 21(4):935-9. PMID: 1917622.
      Citations:    
    63. Lai PP, Pilepich MV, Krall JM, Asbell SO, Hanks GE, Perez CA, Rubin P, Sause WT, Cox JD. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radiat Oncol Biol Phys. 1991 Sep; 21(4):925-33. PMID: 1917621.
      Citations:    
    64. Yesner R, Seydel GH, Asbell SO, Cox JD, Bauer M, Shin KH, Byhardt R, Perez C. Biopsies of non-small cell lung cancer: central review in cooperative studies of the Radiation Therapy Oncology Group. Mod Pathol. 1991 Jul; 4(4):432-5. PMID: 1656431.
      Citations:    
    65. Order S, Pajak T, Leibel S, Asbell S, Leichner P, Ettinger D, Stillwagon G, Herpst J, Haulk T, Kopher K, et al. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys. 1991 May; 20(5):953-63. PMID: 1850722.
      Citations:    
    66. Stillwagon GB, Order SE, Guse C, Leibel SA, Asbell SO, Klein JL, Leichner PK. Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01. Int J Radiat Oncol Biol Phys. 1991 Jan; 20(1):65-71. PMID: 1847127.
      Citations:    
    67. Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys. 1991 Jan; 20(1):53-8. PMID: 1993631.
      Citations:    
    68. Leibel SA, Guse C, Order SE, Hendrickson FR, Komaki RU, Chang CH, Brady LW, Wasserman TH, Russell KJ, Asbell SO, et al. Accelerated fractionation radiation therapy for liver metastases: selection of an optimal patient population for the evaluation of late hepatic injury in RTOG studies. Int J Radiat Oncol Biol Phys. 1990 Mar; 18(3):523-8. PMID: 2180867.
      Citations:    
    69. Asbell SO, Martz KL, Pilepich MV, Baerwald HH, Sause WT, Doggett RL, Perez CA. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG phase III study for A2 and B prostate carcinoma. Int J Radiat Oncol Biol Phys. 1989 Nov; 17(5):945-51. PMID: 2808056.
      Citations:    
    70. Jayaraman S, Johnston SA, Sabina SA, Baker AS, Asbell SO. Variation of lung density corrections in a typical patient population. Med Dosim. 1989 Sep; 14(3):179-84. PMID: 2513824.
      Citations:    
    71. Hammond ME, Sause WT, Martz KL, Pilepich MV, Asbell SO, Rubin P, Myers RP, Farrow GM. Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma. Cancer. 1989 Feb 01; 63(3):461-6. PMID: 2463874.
      Citations:    
    72. Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, Perez CA. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys. 1988 Dec; 15(6):1307-16. PMID: 3058656.
      Citations:    
    73. Cox JD, Guse C, Asbell S, Rubin P, Sause WT. Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1988 Dec; 15(6):1331-6. PMID: 3058657.
      Citations:    
    74. Pilepich MV, Asbell SO, Krall JM, Baerwald WH, Sause WT, Rubin P, Emami BN, Pidcock GM. Correlation of radiotherapeutic parameters and treatment related morbidity--analysis of RTOG Study 77-06. Int J Radiat Oncol Biol Phys. 1987 Jul; 13(7):1007-12. PMID: 3597142.
      Citations:    
    75. Pilepich MV, Bagshaw MA, Asbell SO, Hanks GE, Krall JM, Emami BN, Bard RH. Radical prostatectomy or radiotherapy in carcinoma of prostate. The dilemma continues. Urology. 1987 Jul; 30(1):18-21. PMID: 3111057.
      Citations:    
    76. Pilepich MV, Bagshaw MA, Asbell SO, Hanks GE, Krall JM, Emami BN, Bard RH. Definitive radiotherapy in resectable (stage A2 and B) carcinoma of the prostate--results of a nationwide overview. Int J Radiat Oncol Biol Phys. 1987 May; 13(5):659-63. PMID: 3570891.
      Citations:    
    77. Salazar OM, Rubin P, Hendrickson FR, Komaki R, Poulter C, Newall J, Asbell SO, Mohiuddin M, Van Ess J. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer. 1986 Jul 01; 58(1):29-36. PMID: 2423225.
      Citations:    
    78. Lenhard RE, Order SE, Spunberg JJ, Asbell SO, Leibel SA. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol. 1985 Oct; 3(10):1296-300. PMID: 4045523.
      Citations:    
    79. Pilepich MV, Krall J, George FW, Asbell SO, Plenk HD, Johnson RJ, Stetz J, Zinninger M, Walz BJ. Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1984 Oct; 10(10):1861-7. PMID: 6386761.
      Citations:    
    80. Pilepich MV, Asbell SO, Mulholland GS, Pajak T. Surgical staging in carcinoma of the prostate: the RTOG experience. Radiation Therapy Oncology Group. Prostate. 1984; 5(5):471-6. PMID: 6483687.
      Citations:    
    81. Pilepich MV, Pajak T, George FW, Asbell SO, Stetz J, Zinninger M, Plenk HP, Johnson RJ, Mulholland SG, Walz BJ, Kalish L. Preliminary report on phase III RTOG studies of extended-field irradiation in carcinoma of the prostate. Am J Clin Oncol. 1983 Aug; 6(4):485-91. PMID: 6346857.
      Citations:    
    82. Ydrach AA, Marcial VA, Parsons J, Concannon J, Asbell SO, George F. Misonidazole and unconventional radiation in advanced squamous cell carcinoma of the esophagus: a phase II study of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr; 8(3-4):357-9. PMID: 6809704.
      Citations:    
    83. Asbell SO. CT scanning in the male genital tract and in recurrent rectal carcinoma: a review. J Comput Tomogr. 1981 Aug; 5(3):244-55. PMID: 7285616.
      Citations:    
    84. Salazar OM, Rubin P, Hendrickson FR, Poulter C, Zagars G, Feldman MI, Asbell S, Doss L. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. Int J Radiat Oncol Biol Phys. 1981 Jun; 7(6):773-81. PMID: 6169699.
      Citations:    
    85. Leibel SA, Order SE, Rominger CJ, Asbell SO. Palliation of liver metastases with combined hepatic irradiation and misonidazole. Results of a Radiation Therapy Oncology Group Phase I-II study. Cancer Clin Trials. 1981; 4(3):285-93. PMID: 6169464.
      Citations:    
    86. Asbell SO, Schlager BA, Baker AS. Revision of treatment planning for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1980 Jul; 6(7):861-5. PMID: 7204122.
      Citations:    
    87. Asbell SO, Siu J, Lightfoot DA, Brady LW. Individualized eye shields for use in electron beam therapy as well as low-energy photon irradiation. Int J Radiat Oncol Biol Phys. 1980 Apr; 6(4):519-21. PMID: 7390934.
      Citations:    
    88. Schlager B, Asbell SO, Baker AS, Sklaroff DM, Seydel HG, Ostrum BJ. The use of computerized tomography scanning in treatment planning for bladder carcinoma. Int J Radiat Oncol Biol Phys. 1979 Jan; 5(1):99-103. PMID: 422422.
      Citations:    
    89. Wallner PE, Vonderheid EC, Brady LW, Van Scott EJ, Asbell SO. Evaluation and recommendations for therapy of advanced mycosis fungoides lymphoma. Int J Radiat Oncol Biol Phys. 1979 Jan; 5(1):23-7. PMID: 106034.
      Citations:    
    90. Asbell SO, Gadol N, Saluk P, Vonderheid EC, Brady LW. Antibody-dependent cellular cytotoxicity in patients with mycosis fungoides and S?zary syndrome. Int J Radiat Oncol Biol Phys. 1978 Jul-Aug; 4(7-8):609-13. PMID: 101489.
      Citations:    
    91. Wallner PE, Brady LW, Loughead J, Matsumoto T, Antoniades J, Prasasvinichai S, Glassburn JR, Asbell SO, Damsker JI. Subtotal mastectomy and radiation therapy in the definitive management of localized breast malignancy. AJR Am J Roentgenol. 1976 Sep; 127(3):505-7. PMID: 183541.
      Citations:    
    92. Markoe AM, Asbell SO, Weidanz WP, Saluk P, Antoniades K, Brady LW. Effect of acute and fractionated partial body x-irradiation on circulating immunoglobulin levels in mice. Int J Radiat Oncol Biol Phys. 1976 Mar-Apr; 1(5-6):465-70. PMID: 972107.
      Citations:    
    93. Brady LW, Antoniades J, Prasasvinichai S, Torpie RJ, Asbell SO, Glassburn JR. Preoperative radiation therapy. A plan for combined therapy by the Radiation Therapy Oncology Group and the Central Oncology Group. Cancer. 1974 Sep; 34(3):suppl:960-4. PMID: 4853738.
      Citations:    
    94. Brady LW, Lewis GC, Antoniades J, Prasasvinichai S, Torpie RJ, Asbell SO, Glassburn JR, Schatanoff D, MacMurray T. Evolution of radiotherapeutic techniques. Gynecol Oncol. 1974 Aug; 2(2-3):314-23. PMID: 4457407.
      Citations:    
    Asbell's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (288)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _